RE: RNS6 Jun 2020 23:09
Rorkes,
In their latest RNS the fundraiser for their cancer plays. Most drugs are not even at pre clinical stages. I think one of 5 drugs is. Top of my head.
I don’t dispute the potential at all in Avct, if they can nail the tests they’ll kill it. I’m invested for that. But I can’t get my head around how TILS have StemprintER, one drug at phase IIb, and the crown jewel entering phase II. The covid play, and I’m sure they have other bits and be stuck at 100p.
It takes an awful lot of time and costs into the millions to move from pre clinical to phase I and then to phase II. And it’s not a guaranteed success either. And yet still we are languishing behind.
Please don’t assume I’m against AVCT, I’m there and I can happily prove by showing my share certs. I guess I’m just saying the TILS is due a serious rerate if AVCT is correctly priced. Almost like a 100% rerate would just be scratching the surface.